Magdeburg, November 8, 2007 - KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS), today announced the start of a new clinical study. The placebo-controlled, double blind, dose escalating study in healthy individuals will evaluate the tolerability and pharmacokinetics of KN38-7271, a cannabinoid receptor agonist, to treat stroke patients.
